SCHEMBL6893201

SCHEMBL6893201

Nc1cc(-c2ccc3[nH]ncc3c2)nc2c(-c3cnc4ccccc4c3)cnn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 6/20 0.41
GSK3B P49841 5/20 0.41
ROCK2 O75116 5/20 0.41
AURKB Q96GD4 3/20 0.41
PIM3 Q86V86 4/20 0.41
PIM2 Q9P1W9 2/20 0.41
CLK2 P49760 3/20 0.41
CDK5 Q00535 3/20 0.41
DYRK1A Q13627 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
CDK2 P24941 3/20 0.41
MAPK1 P28482 2/20 0.41
DYRK3 O43781 2/20 0.41
CLK1 P49759 1/20 0.41
CLK3 P49761 1/20 0.41
CDK5R1 Q15078 1/20 0.41
DYRK2 Q92630 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
CHEK1 O14757 1/20 0.41
CCNA2 P20248 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10234081 0.96 TRPA1 (0.42) PIM1GSK3BROCK2AURKBCLK2
SCHEMBL6893210 0.85 KDM4E (0.43) PIM1PIM3PIM2CLK2CLK4
SCHEMBL6894598 0.84 CSNK2A1 (0.41) PIM1PIM3PIM2CDK2MAPK1
SCHEMBL7876265 0.82 KDM4E (0.43) PIM1PIM3PIM2CDK2MAPK1
SCHEMBL6893512 0.80 MAPT (0.47) MAPK1PDGFRBPDGFRAKDM4EMEN1
SCHEMBL6894548 0.80 MEN1 (0.42) PIM1PIM3PIM2CDK2MAPK1
SCHEMBL6893413 0.79 MAPT (0.44) CDK2MAPK1CHEK1CCNA2CCNA1
SCHEMBL10234075 0.78 CHEK1 (0.46) GSK3BCLK2DYRK1ACDK2MAPK1
SCHEMBL6894246 0.78 MEN1 (0.43) PIM1PIM3PIM2CLK2DYRK1A
SCHEMBL6894509 0.78 FYN (0.44) MAPK1KDM4EMEN1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 PIM1 3818/4885GSK3B 881/4885ROCK2 4246/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR PIM1 255/4885GSK3B 1818/4885ROCK2 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.